TrialCancer immunology, immunotherapy : CII2023

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study.

Emiel A De Jaeghere et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.